Leerink Partnrs Increases Earnings Estimates for Illumina

Illumina, Inc. (NASDAQ:ILMN) – Equities researchers at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for Illumina in a research note issued to investors on Thursday, October 30th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will earn $4.79 per share for the year, up from their previous forecast of $4.52. The consensus estimate for Illumina’s current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina’s Q4 2025 earnings at $1.30 EPS, Q2 2026 earnings at $1.20 EPS, Q3 2026 earnings at $1.32 EPS, Q4 2026 earnings at $1.47 EPS, FY2026 earnings at $5.13 EPS and FY2027 earnings at $6.26 EPS.

A number of other research firms also recently issued reports on ILMN. UBS Group boosted their target price on shares of Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Barclays boosted their target price on shares of Illumina from $95.00 to $100.00 and gave the company an “underweight” rating in a research report on Friday. Evercore ISI boosted their target price on shares of Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Stephens set a $110.00 target price on shares of Illumina and gave the company an “overweight” rating in a research report on Monday, August 4th. Finally, Wall Street Zen downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Five investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $115.00.

Illumina Price Performance

Illumina stock opened at $116.86 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. Illumina has a 52-week low of $68.70 and a 52-week high of $156.66. The stock’s 50 day moving average price is $99.18 and its two-hundred day moving average price is $93.56. The stock has a market capitalization of $17.96 billion, a price-to-earnings ratio of 14.79, a PEG ratio of 2.34 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.16 by $0.18. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm’s revenue was up .4% on a year-over-year basis. During the same period in the prior year, the business posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS.

Hedge Funds Weigh In On Illumina

A number of large investors have recently modified their holdings of ILMN. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Illumina by 9.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 4,673 shares of the life sciences company’s stock valued at $371,000 after purchasing an additional 404 shares during the last quarter. Vontobel Holding Ltd. raised its holdings in shares of Illumina by 109.6% in the first quarter. Vontobel Holding Ltd. now owns 12,451 shares of the life sciences company’s stock valued at $988,000 after purchasing an additional 6,510 shares during the last quarter. GF Fund Management CO. LTD. raised its holdings in shares of Illumina by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 4,061 shares of the life sciences company’s stock valued at $322,000 after purchasing an additional 731 shares during the last quarter. IFM Investors Pty Ltd raised its holdings in shares of Illumina by 11.4% in the first quarter. IFM Investors Pty Ltd now owns 32,372 shares of the life sciences company’s stock valued at $2,568,000 after purchasing an additional 3,309 shares during the last quarter. Finally, Brown Advisory Inc. raised its holdings in shares of Illumina by 52.1% in the first quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company’s stock valued at $230,818,000 after purchasing an additional 996,589 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.